SBIR/STTR Research Award

METHOD FOR DEVELOPING IMPROVED GENE INHIBITORS

Award identifier d69df9cda7cff2ba4de7efa3763fc939a43881b88980673a51d65910943f1bb9Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$171,300

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Somagenics, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
NWMCAECH9RX7
Solicitation number
Not reported
Topic code
Not reported

Research abstract

The goal of this proposal is to develop a universal method for rapidly deriving effective inhibitors for any gene of interest. Accomplishing this goal requires two steps: 1) selecting an accessible site on the mRNA, and 2) designing an effective molecule that will recognize that site and bind to it, or inactivate it by some other means. Currently available antisense technology and accessible target site selection is still in its infancy and unreliable. Therefore we propose a novel and general approach for rapidly developing an effective technology for mapping accessible target sites in any RNA as well as engineering effective inhibitors to those mapped accessible sites. We accomplish this by using random libraries of antisense sequences that, functioning inside the cell where the target is in its natural conformation, automatically identify the most accessible sites in any desired target RNA. By employing those identified accessible sites, we will engineer our proprietary, topology-based antisense design, RNA Padlocks, for targeted inhibition of mRNA of any desired gene. PROPOSED COMMERCIAL APPLICATIONS: Antisense technologies are currently hindered by the poor ability of oligonucleotides to bind to most sites on target mRNAs, and the difficulty of identifying those sites to which they can bind. By overcoming this hurdle, we will help realize the great possibilities of rational drug design and drug target validation that antisense technology originally promised.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

39 SBIR/STTR records share this UEI (1994–2020). Reported award amounts total $23,258,381. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.